Literature DB >> 7849489

Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates.

A A Padmapriya1, J Tang, S Agrawal.   

Abstract

Synthesis of oligonucleotides has been carried out on 1-, 2-, and 5-mmol scales using an appropriately modified automated, commercially available DNA synthesizer. The reaction cycles were optimized to obtain efficient coupling (> or = 97%). The synthesized oligonucleotide was purified by preparative reversed-phase liquid chromatography, followed by detritylation and desalting to obtain the oligonucleotides in the Na+ form. The purified oligonucleotides were characterized by 31P NMR, mass spectrometry, capillary gel electrophoresis, and ion-exchange high-performance liquid chromatography. By using these protocols, a 25-mer oligodeoxyribonucleotide can be synthesized on a 1-, 2-, or 5-mmole scale to obtain approximately 2.4, 4.8, or 12 g of purified product.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7849489     DOI: 10.1089/ard.1994.4.185

Source DB:  PubMed          Journal:  Antisense Res Dev        ISSN: 1050-5261


  13 in total

1.  Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication.

Authors:  G Harth; P C Zamecnik; J Y Tang; D Tabatadze; M A Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Self-neutralizing oligonucleotides with enhanced cellular uptake.

Authors:  Ivan Yanachkov; Boris Zavizion; Valeri Metelev; Laura J Stevens; Yekaterina Tabatadze; Milka Yanachkova; George Wright; Anna M Krichevsky; David R Tabatadze
Journal:  Org Biomol Chem       Date:  2017-02-07       Impact factor: 3.876

3.  Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

Authors:  H Wang; Q Cai; X Zeng; D Yu; S Agrawal; R Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

4.  Improvement in the synthesis of oligonucleotides of extended length by modification of detritylation step.

Authors:  I Habus; S Agrawal
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

5.  Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology.

Authors:  Günter Harth; Marcus A Horwitz; David Tabatadze; Paul C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

6.  Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis.

Authors:  Günter Harth; Paul C Zamecnik; David Tabatadze; Katherine Pierson; Marcus A Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

7.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.

Authors:  S Agrawal; Z Jiang; Q Zhao; D Shaw; Q Cai; A Roskey; L Channavajjala; C Saxinger; R Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion.

Authors:  Paul C Zamecnik; Malay K Raychowdhury; David R Tabatadze; Horacio F Cantiello
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

9.  Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains.

Authors:  E Rapaport; A Levina; V Metelev; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

10.  Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides.

Authors:  R H Barker; V Metelev; E Rapaport; P Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.